Why this undervalued ASX 200 biotech share is worth a closer look

Although global economic sentiment remains grim, here's why I think PolyNovo Ltd (ASX: PNV) is a buy if the markets continue to fall.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus pandemic and the oil trade-war between Saudi Arabia and Russia have wreaked havoc across global markets over the last four weeks shedding over 25% from both the S&P/ASX 200 Index (ASX: XJO) and the Dow Jones Industrial Average.

Among those heavily affected is Australian biotech company PolyNovo Ltd (ASX: PNV), which has seen its share price fall a staggering 46% from its 52-week high of $3.28 to $1.78 at Friday's close.

Although global economic sentiment remains grim, here's why I think PolyNovo is a buy if the markets continue to fall.

Coronavirus: Little impact on PolyNovo

On 11 March 2020, PolyNovo released an announcement to ease investors minds in regards to the impact of coronavirus on the company's operations.

On the supply side, PolyNovo does not source any raw materials from China and has multiple supplier redundancies built into their supply chain. Additionally, the company has enough finished product on shelves to meet anticipated sales for a significant time period with enough material inventory for the remainder of the year. As a result, the company currently does not anticipate any significant supply chain disruptions in its operations throughout Australia, New Zealand, the United States, and the United Kingdom.

On the demand side, PolyNovo does not sell into China. The main uses of PolyNovo's flagship product NovoSorb is in emergency, traumatic, or extensive surgery applications. These surgeries are anticipated to continue regardless of the coronavirus as these procedures are generally not elective surgeries. Therefore, the nature of NovoSorb allows product demand to remain predictable going forward.

What is NovoSorb?

PolyNovo has used a base polymer created by CSIRO to create NovoSorb – a polymer with foaming processes and new formulations specifically for medical devices. These polymers work by supporting different functions of the body and then harmlessly biodegrading through absorption or excretion.

The main application of NovoSorb is NovoSorb Biodegradable Temporising Matrix (BTM), a man-made synthetic polymer designed to help surgeons treat traumatic wounds. NovoSorb BTM is used to temporarily close wounds and aid the body in generating new tissue.

NovoSorb has achieved regulatory approval in a substantial number of countries, with 5 additional approvals in process. Commercial revenues have skyrocketed over the last three years with H1 2020 sales amounting to $8.45 million – up 129% from the same period last year. These revenues are expected to continue growing with 2020 sales anticipated to comfortably double 2019 figures.

In addition to scaling NovoSorb globally, PolyNovo also has a strong development pipeline with expansions into hernia devices, breast augmentation/reconstruction, drug elution and beta cell technologies. These developments are on-track with manufacturing and trials to be completed by the end of the year with a total market value estimated at over $6 billion.

Foolish takeaway

Investing in a time of huge volatility is always risky. However, markets falling provide a fantastic opportunity for long-term growth in great companies. With the impact of coronavirus on PolyNovo's operations minimal, PolyNovo is a great company to invest in long-term at these prices.

Motley Fool contributor Jordan Liu has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »